Skip to content
Evigrade
CriticalAntiretroviral, HIV protease inhibitor×Antiepileptics. Barbiturates

Updated · Methodology

Mechanism

Phenobarbital strongly induces the liver enzymes that break down drugs (cytochrome P450 and UDP-glucuronosyltransferases) and the transporter P-glycoprotein, so many drugs are cleared faster and work less well (phenobarbital summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The liver breaks down atazanavir through the enzyme CYP3A4. Strong inducers of this enzyme, phenobarbital among them, can make atazanavir ineffective and lead to viral resistance (atazanavir SmPC, European Medicines Agency, EMA). Atazanavir boosted with cobicistat is even more sensitive to this induction (atazanavir/cobicistat SmPC, EMA). The effect also runs the other way: ritonavir in an atazanavir regimen can lower phenobarbital levels by inducing CYP2C9 and CYP2C19 (atazanavir SmPC, EMA).

Symptoms

The combination itself usually causes no symptoms: atazanavir loses its effect, the human immunodeficiency virus (HIV) viral load rises, and the virus may become resistant to treatment (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and atazanavir label, US Food and Drug Administration, FDA). A rising viral load shows only on blood tests. Ritonavir can lower phenobarbital levels (atazanavir SmPC, EMA), and seizures may become more frequent when anticonvulsant levels fall. Stopping phenobarbital abruptly after long use in a person dependent on it can cause delirium, seizures and even death (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is contraindicated. Atazanavir is contraindicated with strong CYP3A4 inducers, and phenobarbital is named among them, both with and without ritonavir (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPC, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). Atazanavir is also on the list of contraindicated drugs in the phenobarbital SmPC (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Do not stop phenobarbital abruptly: reduce the dose gradually (phenobarbital SmPC, AEMPS). The interaction table of the same atazanavir SmPC keeps a softer row: phenobarbital is used with caution in the ritonavir-boosted regimen, and without ritonavir the combination is not recommended. The contraindications section of this SmPC is stricter (atazanavir SmPC, EMA). If the two drugs have nevertheless been taken together, monitor the virological response closely. With a ritonavir-boosted regimen, the phenobarbital dose may need adjusting (atazanavir SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Phenobarbital